Newtyn Reports Full Exit From Theravance Biopharma With Zero Shares Held
The investment manager's ownership report covered both managed partnerships' holdings as of September 30, 2026.
Newtyn Management, an investment manager for partnerships, reported zero shares of Theravance Biopharma in an SEC ownership amendment filed Monday. The full exit covered holdings as of September 30, 2026.
Both Partnerships Held Zero
Newtyn TE Partners and Newtyn Partners, the partnerships managed by Newtyn Management, each held zero ordinary shares on September 30, 2026.
Newtyn's reported ownership stems from its role managing those partnerships. The manager reported a 0% stake in Theravance's ordinary shares and no voting power, either alone or shared with others.
A Passive Position Ends
Newtyn classified the amendment as an exit disclosure. It also certified that the securities were bought and held without the purpose or effect of influencing or changing Theravance's control.